Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Watch a 1-hour webinar from the 2018 Antibody Engineering & Therapeutics Digital Week titled, “Emerging Technologies for Finding Rare Antibodies,” featuring scientists from Berkeley Lights and Teva Pharmaceuticals.
Find out how Opto™ Plasma B Discovery using the Beacon® optofluidic system accelerates lead molecule discovery against difficult targets.
Discover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B cells in a single day.